1-13 of 13 results for subject:Information
Librarians' tools
- Search time
- 0.19 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:Information
- We searched for
- subject_t:Information OR subject_ses:91662
Answering member
X
Lord Darzi of Denham
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Darzi of Denham, Lord (13)
Legislative stage
Legislation
Subject
Publisher
My Lords, the National Cancer Action Team is working with cancer networks and cancer charities to develop an electronic delivery system that can be used by professionals to deliver information prescriptions to patients at any point during their cancer journey. Eleven tumour-specific information pathways have been developed and are being piloted across 71 sites in England. It is planned that the full system will be available and that all cancer patients will receive an information prescription as part of their consultation from 2010.
My Lords, the National Cancer Action Team is working with cancer networks and cancer charities to develop an electronic delivery system that can be used by professionals to deliver information prescriptions to patients at any point during their cancer journey. Eleven tumour-specific information pathways have been developed and are being piloted across 71 sites in England. It is planned that the full system will be available and that all cancer patients will receive an information prescription as part of their consultation from 2010.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Lord Clement-Jones
(Liberal Democrat)
Type
Oral answers to questions
To ask Her Majesty’s Government when all cancer patients will receive an information prescription.
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1307
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, that is correct. The information prescription pilots are addressing, first, the concept of the dispensing of patient prescription information by a clinical nurse specialist who has all the competencies to explain the content of such prescription information. In addition, a written consultation discussion will be recorded and explained by the consultant; prescribing and dispensing information with a palliative care setting will be given; and there will be patient self-prescribing, with an explanation of what the content of that prescription means.
My Lords, that is correct. The information prescription pilots are addressing, first, the concept of the dispensing of patient prescription information by a clinical nurse specialist who has all the competencies to explain the content of such prescription information. In addition, a written consultation discussion will be recorded and explained by the consultant; prescribing and dispensing information with a palliative care setting will be given; and there will be patient self-prescribing, with an explanation of what the content of that prescription means.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Lord Clement-Jones
(Liberal Democrat)
Type
Oral answers to questions
My Lords, I thank the Minister for that reply; it is welcome news. The pilot scheme is obviously taking slightly longer than anticipated; the cancer reform strategy promised the information prescription in 2009. Nevertheless, I welcome the news. Can the Minister say whether, along with the information prescription, all patients will have the assistance of a healthcare professional in helping them to understand and act on the information prescription made available?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1307
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, I agree. I can say that patients’ satisfaction and experience tremendously improved when I started to work for the specialist nurse in my colorectal team. I could not agree more; we need to develop specialist nurses and the roles that they will play, but that needs a significant mindset shift, certainly on the part of many of my nursing colleagues, as well as the development of competencies in providing that type of service.
My Lords, I agree. I can say that patients’ satisfaction and experience tremendously improved when I started to work for the specialist nurse in my colorectal team. I could not agree more; we need to develop specialist nurses and the roles that they will play, but that needs a significant mindset shift, certainly on the part of many of my nursing colleagues, as well as the development of competencies in providing that type of service.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Lord Walton of Detchant
(Crossbench)
Type
Oral answers to questions
My Lords, I am grateful that the Minister expressed support for the concept of specialist nurses working in this important field. Specialist nurses are making an increasingly important contribution across many fields in the National Health Service, particularly in supporting and helping patients suffering from a variety of progressive diseases such as Parkinson’s, epilepsy, multiple sclerosis and many more, as well as cancer. May I have an assurance from the Minister that the development of specialist nurse services, not just in cancer but in other fields, is likely to be high on the agenda of the National Health Service?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1309
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, the reason these are called information prescriptions rather than notes is because they contain evidence-based information. As to what this process does to the relationship between the clinician and the patients, I personally think it is transforming it from an era of paternalism into an era of partnership between the patient and the clinician.
My Lords, the reason these are called information prescriptions rather than notes is because they contain evidence-based information. As to what this process does to the relationship between the clinician and the patients, I personally think it is transforming it from an era of paternalism into an era of partnership between the patient and the clinician.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Lord Patel
(Crossbench)
Type
Oral answers to questions
My Lords, I am sure the Minister is well aware that in obstetrics these information prescriptions are more appropriately referred to as patient information notes. In fact, obstetricians were the first to pioneer such notes. How do such notes help the patient-professional relationship? Should these notes record the performance of the surgeon—or the robot, as appropriate—in terms of outcome?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1308
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, I commend Christie’s and many specialist hospitals around the country. I work in one, the Royal Marsden, which provides services not dissimilar to the ones provided by Christie’s. I have little expertise in the banking arrangements of specialist hospitals, but I shall be more than happy to write to my noble friend about the issue.
My Lords, I commend Christie’s and many specialist hospitals around the country. I work in one, the Royal Marsden, which provides services not dissimilar to the ones provided by Christie’s. I have little expertise in the banking arrangements of specialist hospitals, but I shall be more than happy to write to my noble friend about the issue.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Lord Bradley
(Labour)
Type
Oral answers to questions
My Lords, does my noble friend agree that specialist cancer hospitals such as the Christie in Manchester, where I am a non-executive director, already provide excellent information for specialist services, as evidenced by the fact that the hospital came first in the country in the recent in-patient survey for overall care? Does he further agree that the Christie charity provides invaluable additional support through specialist nurses and counsellors to provide disease-specific information, and that that is why the Government’s support to get compensation for the failed UK subsidiary of an Icelandic bank is so essential?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1308
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, we give guidance to PCTs about the information prescription. As it stands, we are running the pilots to learn more from them but, while we are doing so, we also have 25,000 patient questionnaires seeking patients’ views about the information. One thousand, two hundred and fifty patients will be part of the participating pilot while the other half will be the control group without the information prescription, and those are the comparative data on which we hope to build the system in 2010.
My Lords, we give guidance to PCTs about the information prescription. As it stands, we are running the pilots to learn more from them but, while we are doing so, we also have 25,000 patient questionnaires seeking patients’ views about the information. One thousand, two hundred and fifty patients will be part of the participating pilot while the other half will be the control group without the information prescription, and those are the comparative data on which we hope to build the system in 2010.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Baroness Barker
(Liberal Democrat)
Type
Oral answers to questions
My Lords, the evaluation of the information prescription pilots suggested that PCTs needed to be given guidance about commissioning charitable and voluntary organisations to provide support to people to enable them to understand the prescription they have been given. What guidance does the Minister’s department give to PCTs about commissioning information and support services?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1308-9
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, we are working with a large number of charities. I acknowledge the championing and pioneering impact of the work of the late Lady Clement-Jones, who introduced this concept through Cancerbackup and, more recently, Macmillan Cancer Support. We are working with CRUK, the biggest cancer charity in this country, supporting research and the evidence base for these information prescriptions. In addition, at least 32 other charities that deal with cancer are helping us with the content of such information prescriptions.
My Lords, we are working with a large number of charities. I acknowledge the championing and pioneering impact of the work of the late Lady Clement-Jones, who introduced this concept through Cancerbackup and, more recently, Macmillan Cancer Support. We are working with CRUK, the biggest cancer charity in this country, supporting research and the evidence base for these information prescriptions. In addition, at least 32 other charities that deal with cancer are helping us with the content of such information prescriptions.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Earl Howe
(Conservative)
Type
Oral answers to questions
My Lords, what quality assurance is being put in place for information prescriptions?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1308
Chamber / Committee
House of Lords chamber
House
House of Lords
My Lords, this is an academic evaluation so there is a random control trial going on. Patients will be selected at random. That is one of the pilots looking at the impact of this. Our aspiration is that every patient with cancer will receive an information prescription throughout the whole of their pathway, whether that is the referral from the general practitioner to the specialist centre, the diagnosis, the treatment, the long-term follow-up or the prognosis. We believe in empowering patients because many will say that an empowered patient will get through the cancer pathway at a speedier rate and feel much more confident in the treatment they are receiving.
My Lords, this is an academic evaluation so there is a random control trial going on. Patients will be selected at random. That is one of the pilots looking at the impact of this. Our aspiration is that every patient with cancer will receive an information prescription throughout the whole of their pathway, whether that is the referral from the general practitioner to the specialist centre, the diagnosis, the treatment, the long-term follow-up or the prognosis. We believe in empowering patients because many will say that an empowered patient will get through the cancer pathway at a speedier rate and feel much more confident in the treatment they are receiving.
Answered by
Lord Darzi of Denham
(Labour)
Asked by
Baroness Gardner of Parkes
(Conservative)
Type
Oral answers to questions
My Lords, will the Minister tell me, for the benefit of other Members of the House also, quite simply what the information prescription will be, how it will be decided which people will get it—in the pilot, he said, half will get it and half will not—and how you will discover that you are one of the ones who will? Will it just arrive out of the blue in written form, or in another form?
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1309
Chamber / Committee
House of Lords chamber
House
House of Lords
To ask Her Majesty’s Government when all cancer patients will receive an information prescription.
To ask Her Majesty’s Government when all cancer patients will receive an information prescription.
Asked by
Lord Clement-Jones
(Liberal Democrat)
Answered by
Lord Darzi of Denham
(Labour)
Oral questions - Lead
Status
Answered
For answer on
19 May 2009
Answered on
19 May 2009
My Lords, the National Cancer Action Team is working with cancer networks and cancer charities to develop an electronic delivery system that can be used by professionals to deliver information prescriptions to patients at any point during their cancer journey. Eleven tumour-specific information pathways have been developed and are being piloted across 71 sites in England. It is planned that the full system will be available and that all cancer patients will receive an information prescription as part of their consultation from 2010.
Subjects
Cancer; Information; Patients; Prescriptions
Date
19 May 2009
Reference
710 c1307
Chamber / Committee
House of Lords chamber
House
House of Lords
Whether they plan to introduce requirements for patient information leaflets to be prepared to specify the possible risks associated with biosimilar medicines, as appropriate.
Whether they plan to introduce requirements for patient information leaflets to be prepared to specify the possible risks associated with biosimilar medicines, as appropriate.
Asked by
Lord Walton of Detchant
(Crossbench)
Answered by
Lord Darzi of Denham
(Labour)
Type
Written questions
Status
Answered
Answered on
16 January 2008
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisations for the following biosimilar medicines:
Omnitrope (somatropin);
Valtropin (somatropin);
Epoetin alfa hexal, Abseamed, Binocrit (all containing epoetin alfa); and
Silapo, Retacrit (both containing epoetin zeta).
We are not aware of any legal basis for such automatic substitution. Section 58 (2)(a) of the Medicines Act 1968 provides for prescription-only medicines to be sold or supplied only in accordance with a prescription given by an appropriate practitioner. If a branded medicinal product is prescribed, then it must be dispensed. A pharmacist who substitutes another product for a branded drug without first agreeing this with the prescriber would be in breach of medicines legislation.
Patient information leaflets include all the relevant information on usage, side effects etc and reflect the information contained in the Summary of Product Characteristics (SPC). The Government have no plans to call for the introduction of a requirement for patient information leaflets to specify the possible risks associated with the use of biosimilar medicines. If a particular risk is identified in relation to a particular product, the SPC for that product will detail that risk and the patient information leaflet will reflect the SPC.
Subjects
Information; Patients; Prescription drugs; Side effects; Biosimilar medicines
Date
16 January 2008
Reference
1139; 697 c256-7WA
House
House of Lords
Whether they have considered banning the automatic substitution of branded pharmaceutical preparations by comparable biosimilar medicines; and
Whether they have considered banning the automatic substitution of branded pharmaceutical preparations by comparable biosimilar medicines; and
Asked by
Lord Walton of Detchant
(Crossbench)
Answered by
Lord Darzi of Denham
(Labour)
Type
Written questions
Status
Answered
Answered on
16 January 2008
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisations for the following biosimilar medicines:
Omnitrope (somatropin);
Valtropin (somatropin);
Epoetin alfa hexal, Abseamed, Binocrit (all containing epoetin alfa); and
Silapo, Retacrit (both containing epoetin zeta).
We are not aware of any legal basis for such automatic substitution. Section 58 (2)(a) of the Medicines Act 1968 provides for prescription-only medicines to be sold or supplied only in accordance with a prescription given by an appropriate practitioner. If a branded medicinal product is prescribed, then it must be dispensed. A pharmacist who substitutes another product for a branded drug without first agreeing this with the prescriber would be in breach of medicines legislation.
Patient information leaflets include all the relevant information on usage, side effects etc and reflect the information contained in the Summary of Product Characteristics (SPC). The Government have no plans to call for the introduction of a requirement for patient information leaflets to specify the possible risks associated with the use of biosimilar medicines. If a particular risk is identified in relation to a particular product, the SPC for that product will detail that risk and the patient information leaflet will reflect the SPC.
Subjects
Information; Patients; Prescription drugs; Side effects; Biosimilar medicines
Date
16 January 2008
Reference
1138; 697 c256-7WA
House
House of Lords
asked Her Majesty's Government:Which biosimilar medicines have been approved for use in the United Kingdom; and
asked Her Majesty's Government:Which biosimilar medicines have been approved for use in the United Kingdom; and
Asked by
Lord Walton of Detchant
(Crossbench)
Answered by
Lord Darzi of Denham
(Labour)
Type
Written questions
Status
Answered
Answered on
16 January 2008
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisations for the following biosimilar medicines:
Omnitrope (somatropin);
Valtropin (somatropin);
Epoetin alfa hexal, Abseamed, Binocrit (all containing epoetin alfa); and
Silapo, Retacrit (both containing epoetin zeta).
We are not aware of any legal basis for such automatic substitution. Section 58 (2)(a) of the Medicines Act 1968 provides for prescription-only medicines to be sold or supplied only in accordance with a prescription given by an appropriate practitioner. If a branded medicinal product is prescribed, then it must be dispensed. A pharmacist who substitutes another product for a branded drug without first agreeing this with the prescriber would be in breach of medicines legislation.
Patient information leaflets include all the relevant information on usage, side effects etc and reflect the information contained in the Summary of Product Characteristics (SPC). The Government have no plans to call for the introduction of a requirement for patient information leaflets to specify the possible risks associated with the use of biosimilar medicines. If a particular risk is identified in relation to a particular product, the SPC for that product will detail that risk and the patient information leaflet will reflect the SPC.
Subjects
Information; Patients; Prescription drugs; Side effects; Biosimilar medicines
Date
16 January 2008
Reference
1137; 697 c255-7WA
House
House of Lords
asked Her Majesty's Government:How the National Institute for Health and Clinical Excellence might take into account new information pertaining to mortality benefit of a medical technology if that information becomes available after the publication of an appraisal consultation document or final appraisal determination.
asked Her Majesty's Government:How the National Institute for Health and Clinical Excellence might take into account new information pertaining to mortality benefit of a medical technology if that information becomes available after the publication of an appraisal consultation document or final appraisal determination.
Asked by
Lord Jones of Cheltenham
(Liberal Democrat)
Answered by
Lord Darzi of Denham
(Labour)
Type
Written questions
Status
Answered
Answered on
5 December 2007
The National Institute for Health and Clinical Excellence (NICE) makes exhaustive efforts to identify and consider relevant information during the course of an appraisal. New evidence can be submitted to NICE in response to a consultation on an appraisal consultation document (ACD) and, if important and genuinely new evidence becomes available after consultation on an ACD has closed but prior to the issuing of a final appraisal determination (FAD), then NICE will make every effort to consider its impact on the relevant appraisal. However, NICE will not generally consider new evidence once a FAD is issued.
Subjects
Cost effectiveness; Information; Innovation; NHS; Medical treatments; Medical equipment; National Institute for Health and Care Excellence
Date
5 December 2007
Reference
587; 696 c195WA
House
House of Lords